Jan 05,2016

Panasonic Healthcare Holdings completes acquisition of leading Diabetes Care business from Bayer AG

Panasonic Healthcare Holdings, Co., Ltd. ("Panasonic Healthcare") and Bayer Aktiengesellschaft ("Bayer AG") today announced the completion of Panasonic Healthcare’s acquisition of Bayer AG’s Diabetes Care business. Panasonic Healthcare is backed by funds sponsored by leading global investment firm KKR and the Panasonic Corporation. The total consideration for the transaction is around EUR 1 billion (approximately ¥132 billion at the exchange rate of EUR1=¥132).

COLLABORATION MERGERS & ACQUISITION

#product & service

#bgm

View Analyst & Ambassador Comments
Go to original news
Jan 04,2016

Robert Bosch Venture Capital leads $3.1M round in digital diabetes startup

Germany-based digital health startup Emperra has raised $3.1 million in a round led by Robert Bosch Venture Capital with participation from existing investors, Peppermint VenturePartners and Investitionsbank des Landes Brandenburg. Emperra offers a digital diabetes management system that includes connected health devices and software. The company's executives also contributed to the round. Emperra's primary product, Esysta, includes smart insulin pens, wireless-enabled blood glucose meters, and CE-marked software that runs on various platforms including smart TVs, web portals, and mobile apps.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Jan 21,2016

Survey: Diabetes apps are top prospect for developers

The diabetes management space has long held a commanding lead as the most popular target for mobile health developers, according to a new blog post from Research2Guidance based on their mHealth App Developer Economics report, for which the research firm surveyed 5,000 developers. According to R2G, more than 1,500 diabetes apps exist worldwide and the leading publisher of diabetes apps sees about 120,000 downloads per year.

View Analyst & Ambassador Comments
Go to original news
Jan 26,2016

Mobile diabetes intervention reduced HbA1c 2 percentage points more than standard of care

In late 2014, MobiHealthNews reported that Atlanta-based diabetes management company Rimidi was piloting its software in a 129-patient RCT with Desert Oasis Healthcare, part of Heritage California ACO, a pioneer ACO. Now the company has made public some of the preliminary results from the ongoing study, showing that patients who used Rimidi’s intervention dropped their HbA1c by 2 percentage points more than standard treatments and their total cholesterol by 50 mg/dL more than standard treatments.

CLINICAL STUDY

#mobile app

#bgm

View Analyst & Ambassador Comments
Go to original news
Jan 04,2016

BD to Present at the 34th Annual J. P. Morgan Healthcare Conference

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the 34th Annual J. P. Morgan Healthcare Conference on Wednesday, January 13, 2016, at 12:00 p.m. EST.

View Analyst & Ambassador Comments
Go to original news
Jan 05,2016

Insulet Partners with Glooko as its Preferred Data Management Partner for OmniPod Patients and Healthcare Providers

Insulet Corporation, the leader in tubeless insulin pump technology with its OmniPod Insulin Management System, today announced it has partnered with Glooko, the leader in diabetes management mobile and web applications, to provide U.S. OmniPod patients and healthcare providers a new data management system named "Insulet Provided Glooko". This new system enables healthcare professionals to easily download patients' data from multiple devices and review a robust set of print and online reports during patient visits, including access to detailed insights about their patients' care plans.

COLLABORATION PARTNERSHIP

#connected device

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Jan 07,2016

BD Announces Live Webcast of First Fiscal Quarter Earnings Conference Call

BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will conduct a live webcast of its first fiscal quarter 2016 earnings conference call on Wednesday, February 3, 2016, at 8:00 a.m. (ET).

View Analyst & Ambassador Comments
Go to original news
Jan 11,2016

Insulet Enters into Development Agreement with Eli Lilly for OmniPod Delivery of U200 Concentrated Insulin

Insulet Corporation today announced it has entered into a development agreement with Eli Lilly and Company to develop a new version of Insulet's OmniPod tubeless insulin delivery system, specifically designed to deliver Lilly's Humalog 200 units/mL insulin.

COLLABORATION PARTNERSHIP

#r&d

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Jan 11,2016

Insulet Corporation to Present at Upcoming Investor Conference

Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced that management will present at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, California on January 12, 2016 at 10:00am (Pacific Time).

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Jan 12,2016

Tandem Diabetes Care Amends Term Loan Facility with CRG

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM) today announced the amendment of its term loan facility with Capital Royalty Partners II, L.P. and its affiliate funds ("CRG"), which will provide the Company access to $50 million in addition to the $30 million borrowed from CRG in January 2013.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES